Avalon Pharma Posts Growth in H1 Net Profit, Revenue

MT Newswires · 2d ago
01:35 AM EDT, 08/06/2026 (MT Newswires) -- Middle East Pharmaceutical Industries Co. (SASE:4016), d/b/a Avalon Pharma, said Thursday that attributable net profit and revenue for the first half grew year over year. Net profit attributable to shareholders of the issuer for the six months ended June 30 was 55.7 million Saudi riyals, compared with 44.2 million riyals earlier. EPS moved to 1.59 riyals from 1.26 riyals. The Tadawul-listed pharmaceutical company's revenue was 266.6 million riyals, compared with 215 million riyals a year ago.